Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Equity Income (2016 - 2020)

Historic Equity Income for Ligand Pharmaceuticals (LGND) over the last 6 years, with Q1 2020 value amounting to -$25.5 million.

  • Ligand Pharmaceuticals' Equity Income fell 24720.41% to -$25.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$39.9 million, marking a year-over-year decrease of 19265.69%. This contributed to the annual value of $2.9 million for FY2019, which is 9394.02% down from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Equity Income of -$25.5 million as of Q1 2020, which was down 24720.41% from $8.5 million recorded in Q4 2019.
  • Ligand Pharmaceuticals' Equity Income's 5-year high stood at $59.9 million during Q3 2018, with a 5-year trough of -$74.0 million in Q4 2018.
  • For the 5-year period, Ligand Pharmaceuticals' Equity Income averaged around $180705.9, with its median value being -$1.2 million (2017).
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Equity Income was 597546.61% (2018), while the steepest drop was 175817.65% (2018).
  • Over the past 5 years, Ligand Pharmaceuticals' Equity Income (Quarter) stood at -$9.0 million in 2016, then surged by 149.64% to $4.5 million in 2017, then tumbled by 1758.18% to -$74.0 million in 2018, then surged by 111.46% to $8.5 million in 2019, then tumbled by 400.19% to -$25.5 million in 2020.
  • Its Equity Income stands at -$25.5 million for Q1 2020, versus $8.5 million for Q4 2019 and -$10.5 million for Q3 2019.